MedTrace Logo

Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2

NCT04907331 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3000

Last updated 2021-09-10

No results posted yet for this study

Summary

This study will analyze the safety and efficacy of the heterologous vaccination with Vaxzevria followed by Comirnaty. As a control individuals will be vaccinated with Comirnaty or Vaxzevria twice. Each arm will involve 1000 individuals. Endpoints will be the level of antibody and T cell response as well as frequency of vaccine failures.

Conditions

  • SARS-CoV2 Infection

Interventions

BIOLOGICAL

Vaxzevria

The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria followed by Comirnaty

BIOLOGICAL

Comirnaty

The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria

Sponsors & Collaborators

  • Medical University of Graz

    collaborator OTHER

  • Medical University of Vienna

    collaborator OTHER

  • Medical University Innsbruck

    lead OTHER

Principal Investigators

  • Dorothee von Laer, MD · Medical University Innsbruck

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-10
Primary Completion
2021-11-30
Completion
2021-12-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04907331 on ClinicalTrials.gov